Table 1.
Baseline Characteristics of the 113 Participants Treated With Combination Direct-Acting Antivirals
| Baseline Characteristic | Mean (Standard Deviation), n (%) |
|---|---|
| Demographic factors | |
| Age, years | 51.8 (10.1) |
| Age ≥50 years | 70 (62.0) |
| Race/Ethnicity | |
| Black | 31 (27.4) |
| Hispanic/Latino/a | 62 (54.9) |
| White | 11 (9.7) |
| Other | 9 (8.0) |
| Male | 67 (59.3) |
| Employed | 22 (19.5) |
| Married/Cohabitation | 40 (35.4) |
| Unstable housing | 28 (24.8) |
| High school or higher | 69 (61.1) |
| Clinical factors | |
| Also living with human immunodeficiency virus | 13 (11.5) |
| Cirrhosis | 31 (27.4) |
| HCV subtype 1a | 94 (83.2) |
| IL28B TC/TT | 89 (78.8) |
| Depression (Beck depression inventory score ≥20) | 41 (36.3) |
| Psychiatric illness | 53 (46.9) |
| Alcohol intoxication 30 days prior | 25 (22.1) |
| Medication factors | |
| Length of planned treatment, weeks | |
| 8 | 31 (27.4) |
| 12 | 74 (65.5) |
| 24 | 8 (7.1) |
| HCV treatment-naive | 98 (86.7) |
| Combination direct-acting antiviral regimen | |
| Sofosbuvir/Ledipasvir | 102 (90.3) |
| Sofosbuvir/Simeprevir | 11 (9.7) |
| Any drug use | |
| 6 months prior to baseline | 72 (63.7) |
| At baseline | 55 (48.8) |
| During treatment | 81 (71.7) |
Abbreviation: HCV, hepatitis C virus.